Sara Tolaney

106PUBLICATIONS

571CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityEconomic models and forecasting

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (106)

Sort by Publication Date:

|Jul 13, 2026

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

|Jun 05, 2026

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

|May 15, 2026

Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.

|May 13, 2026

Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.

|Mar 23, 2026

The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets.

Jessica K Lee, Julia C F Quintanilha, Kuei-Ting Chen

|Feb 27, 2026

The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS).

Sarah L Sammons, Thomas M Kuntz, Molly DiLullo

Pageof 18

Frequent Collaborators

17 joint publications

Paolo Tarantino

17 joint publications

Ann Partridge

15 joint publications

Hope S Rugo

15 joint publications

Nabihah Tayob

14 joint publications

Eric Winer

13 joint publications

Elizabeth Mittendorf

13 joint publications

Nancy U Lin

11 joint publications

Rinath Jeselsohn

11 joint publications

Filipa Lynce

10 joint publications

Ana Garrido-Castro

Frequent Collaborators

17 joint publications

Paolo Tarantino

17 joint publications

Ann Partridge

15 joint publications

Hope S Rugo

15 joint publications

Nabihah Tayob